Moreover, transferrin and TIBC were significantly increased after treatment of roxadustat in both DD-CKD patient group (for transferrin: WMD: 0.40; 95% CI: 0.30–0.50; p < 0.00001; for TIBC: WMD: 43.65; 95% CI: 33.78–53.53; p < 0.00001; Figures 4B,C and Table 3) and in NDD-CKD patient group (for transferrin: WMD: 0.60; 95% CI: 0.24–0.95; p = 0.0009; for TIBC: WMD: 59.90; 95% CI: 38.85–80.96; p < 0.00001; Figures 4B,C and Table 3). Here, TF is linked to Neurodevelopmental delay.